MedDataX Logo

Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer

NCT ID: NCT07267247

Last Updated: 2025-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-01

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

NCT03544814

Lung Adenocarcinoma EGFR Activating Mutation
COMPLETED PHASE2

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

NCT02575560

EGFR-TKI Resistant Mutation
COMPLETED

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02960607

Carcinoma, Non-Small-Cell Lung
UNKNOWN PHASE2

First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

NCT00339586

Lung Neoplasms Non-Small Cell Lung Cancer Adenocarcinoma, Bronchiolo-Alveolar
UNKNOWN PHASE2

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

NCT04974866

Carcinoma, Adenoid Cystic
RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung) Drug-Related Side Effects and Adverse Reactions (MeSH Term) Egfr Tyrosine Kinase Inhibitor Cardiotoxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EGFR-TKI

Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line.

Intervention Type DRUG

EGFR tyrosine kinase inhibitor

Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with advanced or recurrent EGFR-mutant NSCLC receiving EGFR-TKI treatment

Exclusion Criteria

* NIL
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Taichung Veterans General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mu Han, Peng

Attending Physician, Department of Chest Medicine, Taichung Veterans General Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VGHTC-CM-MHP-20250918

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR
NCT05767866 UNKNOWN PHASE1/PHASE2
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
NCT02886195 UNKNOWN PHASE3
Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer
NCT03461185 UNKNOWN PHASE2
Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC
NCT02353741 TERMINATED PHASE2
Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients
NCT00922025 COMPLETED
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
NCT04324164 RECRUITING
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
NCT06671379 RECRUITING PHASE3
Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)
NCT02475720 COMPLETED
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
NCT04304638 UNKNOWN
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
NCT06071013 RECRUITING PHASE1/PHASE2
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
NCT01775943 UNKNOWN
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC
NCT02988141 UNKNOWN
EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide
NCT03341494 UNKNOWN PHASE2
Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression
NCT01998061 UNKNOWN PHASE2
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
NCT00874419 COMPLETED PHASE3
Chemotherapy of NSCLC With or Without Icotinib
NCT02430974 UNKNOWN PHASE2
Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation
NCT01204307 COMPLETED PHASE2
Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy
NCT01746277 UNKNOWN PHASE2
A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.
NCT01955681 COMPLETED
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients
NCT04552613 COMPLETED NA
Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
NCT02250846 UNKNOWN PHASE2
A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations
NCT03634059 UNKNOWN NA
Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations
NCT06062823 RECRUITING PHASE2
Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
NCT01147211 UNKNOWN PHASE1
Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect
NCT05204758 COMPLETED PHASE3